Compass Pathways plc reported financial results for the three and six months ended June 30, 2026. The company posted a net loss of $253.8 million ($1.88 per share) for Q2 and $162.6 million ($1.33 per share) for H1, driven primarily by non-cash fair value adjustments on warrant liabilities totaling $205.6 million in the quarter. Cash and cash equivalents rose to $433.3 million from $149.6 million at year-end 2025. R&D expenses decreased to $29.2 million for Q2, while G&A increased to $23.2 million due to commercial preparation costs. The company confirmed its rolling NDA submission is on track for completion in Q4 2026, with a commercial launch expected in the first half of 2027 subject to FDA approval and DEA rescheduling. Compass Pathways plc operates as a biotechnology company developing psychedelic-based treatments for mental health conditions.

Compass Pathways plc announced 26-week results from its Phase 3 COMP006 trial of COMP360, a synthetic psilocybin formulation for treatment-resistant depression. In the 25 mg dose arm, 39% of participants achieved a clinically meaningful reduction in MADRS scores by week 6 and maintained benefit through week 26. The company is on track to complete its rolling New Drug Application (NDA) submission to the FDA in Q4 2026, with a potential commercial launch in the first half of 2027. Compass Pathways plc is a biotechnology company developing mental health treatments.